Takeda Pharmaceutical (TAK) Competitors $13.19 -0.08 (-0.60%) (As of 11:46 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TAK vs. SNY, GSK, BNTX, TEVA, BGNE, MRNA, VTRS, SMMT, GMAB, and RDYShould you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include Sanofi (SNY), GSK (GSK), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Takeda Pharmaceutical vs. Sanofi GSK BioNTech Teva Pharmaceutical Industries BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Takeda Pharmaceutical (NYSE:TAK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership. Which has preferable earnings & valuation, TAK or SNY? Sanofi has lower revenue, but higher earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$4.55T0.01$994.06M$0.5822.74Sanofi$48.86B2.51$5.84B$1.9624.69 Is TAK or SNY a better dividend stock? Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 4.0%. Sanofi pays an annual dividend of $1.47 per share and has a dividend yield of 3.0%. Takeda Pharmaceutical pays out 91.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 75.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Does the media prefer TAK or SNY? In the previous week, Sanofi had 2 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 5 mentions for Sanofi and 3 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 0.54 beat Takeda Pharmaceutical's score of 0.17 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sanofi 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in TAK or SNY? Takeda Pharmaceutical received 51 more outperform votes than Sanofi when rated by MarketBeat users. However, 61.25% of users gave Sanofi an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformTakeda PharmaceuticalOutperform Votes10056.82% Underperform Votes7643.18% SanofiOutperform Votes4961.25% Underperform Votes3138.75% Is TAK or SNY more profitable? Sanofi has a net margin of 9.96% compared to Takeda Pharmaceutical's net margin of 6.49%. Sanofi's return on equity of 27.45% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical6.49% 10.00% 4.78% Sanofi 9.96%27.45%15.79% Do insiders & institutionals hold more shares of TAK or SNY? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer TAK or SNY? Sanofi has a consensus price target of $57.50, indicating a potential upside of 18.83%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sanofi 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk & volatility, TAK or SNY? Takeda Pharmaceutical has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. SummarySanofi beats Takeda Pharmaceutical on 18 of the 21 factors compared between the two stocks. Ad Behind the MarketsWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.Take these 4 steps today to protect your retirement NOW Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TAK vs. The Competition Export to ExcelMetricTakeda PharmaceuticalPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$41.97B$6.59B$5.16B$19.05BDividend Yield4.06%2.96%4.96%3.63%P/E Ratio22.7410.6787.2440.02Price / Sales0.01195.421,137.1218.69Price / Cash4.1457.1543.2721.25Price / Book0.835.104.815.23Net Income$994.06M$150.98M$120.16M$989.46M7 Day Performance0.15%1.18%1.17%0.04%1 Month Performance-3.16%-6.44%16.27%-5.70%1 Year Performance-7.57%6.18%28.43%10.90% Takeda Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TAKTakeda Pharmaceutical4.424 of 5 stars$13.19-0.6%N/A-7.0%$41.97B$4.55T22.7449,281SNYSanofi3.2561 of 5 stars$47.95+0.5%$57.50+19.9%-2.0%$121.69B$48.86B24.4686,088Short Interest ↓GSKGSK3.5754 of 5 stars$33.99+1.2%$43.25+27.2%-8.0%$70.45B$31.31B22.0770,200Analyst UpgradeBNTXBioNTech3.2467 of 5 stars$113.75+0.6%$140.76+23.7%+8.0%$27.04B$3.04B-54.176,133TEVATeva Pharmaceutical Industries1.8588 of 5 stars$21.93-0.7%$20.88-4.8%+118.1%$24.84B$16.77B-25.8037,851BGNEBeiGene2.8977 of 5 stars$177.15+0.4%$253.69+43.2%+0.8%$17.27B$3.32B-21.5010,600Positive NewsMRNAModerna4.5067 of 5 stars$39.56+0.4%$79.50+101.0%-59.6%$15.22B$5.06B-6.805,600Options VolumeVTRSViatris1.3123 of 5 stars$12.47-0.4%$13.67+9.6%+15.2%$14.88B$15.05B-16.8538,000SMMTSummit Therapeutics2.2905 of 5 stars$18.66+4.4%$33.33+78.6%+597.7%$13.76B$700,000.00-66.64105GMABGenmab A/S3.9121 of 5 stars$20.59+1.4%$45.20+119.5%-34.0%$13.63B$19.84B19.992,204RDYDr. Reddy's Laboratories1.0394 of 5 stars$15.43+0.4%$17.00+10.2%+14.0%$12.88B$299.87B24.6527,048 Related Companies and Tools Related Companies SNY Competitors GSK Competitors BNTX Competitors TEVA Competitors BGNE Competitors MRNA Competitors VTRS Competitors SMMT Competitors GMAB Competitors RDY Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:TAK) was last updated on 12/30/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredViral Trump video releasedPorter Stansberry’s latest video is going viral… In this bombshell exposé, famed economist Porter Stansberr...Porter & Company | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredElon Musk says U.S. government is going bankruptIn 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Company Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
